Shares of Sarepta Therapeutics SRPT plunged more than 20% yesterday after the company reported the death of a patient after ...

The Company is currently analyzing the case and will update the prescribing information for Elevidys to note this development.

The firm's stock price dropped 27 percent on Tuesday following the news that the young man died from acute liver failure after getting Elevidys.

Data from the EMBARK trial of delandistrogene moxeparvovec in patients with Duchenne muscular dystrophy (DMD) show that ...

A patient has died while receiving Elevidys, a gene therapy for Duchenne muscular dystrophy, marking the first kno ...

Cambridge, Mass.-based Sarepta Therapeutics reported the first known death from its Duchenne muscular dystrophy gene therapy ...

Cargo was founded by two highly acclaimed cell-therapy researchers. The company raised over $500 million to develop ...

We recently published a list of 10 Firms Heavily Hit by Market Pessimism. In this article, we are going to take a look at ...

Shares of Sarepta Therapeutics, Inc. SRPT plunged 27.4% after the company reported a patient death linked to its Elevidys gene therapy, sparking safety concerns. IHS Holding Limited IHS shares surged ...

The plan put forth Tuesday could see the Sackler family pay up to $7 billion. Also in the news: Merck prepares to close its manufacturing plant in Pennsylvania; Optum Rx, which includes UnitedHealth ...

Sarepta will update Elevidys’ label after a patient died following treatment; the FDA issues flu vaccine recommendations ...

Cantor Fitzgerald reiterated their overweight rating on shares of Sarepta Therapeutics (NASDAQ:SRPT – Free Report) in a ...